NEW YORK (Reuters Health) – Long-term glucocorticoid (GC) users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab versus oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone. “Denosumab may be considered as
Men with large upper-bodies have a tendency to favour inequality in society and a limited redistribution of resources. This is the conclusion drawn by Professor Michael Bang Petersen and Associate Professor Lasse Laustsen from the Department of Political Science in a study published in the journal, Political Psychology. “The results challenge the belief that our
Patients using inhaled steroids to control asthma and other breathing problems may be at greater risk for developing nontuberculous mycobacteria (NTM) lung infections, according to new research published online in the Annals of the American Thoracic Society. NTM are in the same family as tuberculosis, but NTM come in many different species and are widely
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok